Neoantigen evolution in cancer: immunoediting, immune escape, and future vaccine strategies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-11 · 1881 (6) · 189741
DOI: 10.1016/j.bbcan.2026.189741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-11. Verfasst von Fernando Martínez-Cortés und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), AP 70228, Ciudad Universitaria, CDMX, CP 04510, Mexico. Die Arbeit nennt 87 Literaturangaben. Gefördert von: National Autonomous University of Mexico Directorate General of Academic Staff Affairs.
Abstract (Originalsprache)
Cancer immunotherapy has changed cancer treatment, with neoantigen-based vaccines emerging as a promising strategy to induce tumor-specific immune responses while minimizing adverse effects on healthy tissues. Advances in next-generation sequencing, immunopeptidomics, artificial intelligence, and computational prediction have accelerated the identification of patient-specific neoantigens and enabled the development of personalized cancer vaccines. Despite encouraging safety profiles and robust induction of neoantigen-specific T-cell responses, clinical efficacy has remained inconsistent. Tumor evolution driven by genomic instability continuously reshapes the neoantigen landscape through intratumoral heterogeneity, immune-mediated selection, and antigen gain or loss, facilitating immune escape and limiting durable therapeutic responses. In addition, T-cell dysfunction and the immunosuppressive tumor microenvironment further compromise vaccine efficacy. In this review, we discuss the origin and diversity of tumor antigens, recent advances in neoantigen identification and vaccine development, and the biological mechanisms that constrain the clinical success of personalized cancer vaccines. We summarize evidence from clinical trials that highlights both the promise and the current limitations of neoantigen-based immunotherapy, and discuss the importance of incorporating tumor evolution into vaccine design. Finally, we present Variable Epitope Libraries (VELs), a vaccine strategy that uses immunogens based on combinatorial libraries of highly mutated epitope variants designed to broaden immune recognition, reduce immune escape, and improve the durability and effectiveness of cancer immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), AP 70228, Ciudad Universitaria, CDMX, CP 04510, Mexico.
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), AP 70228, Ciudad Universitaria, CDMX, CP 04510, Mexico; Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Ciuda…
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), AP 70228, Ciudad Universitaria, CDMX, CP 04510, Mexico. Electronic address: karman@unam.mx.
Förderung
- National Autonomous University of Mexico Directorate General of Academic Staff Affairs
Zitieren
APA
Martínez-Cortés, F., Guzman Valle, J., Maruri, J., Martínez-Zarco, B. A., Domínguez-Romero, A. N., Gevorkian, G., & Manoutcharian, K. (2026). Neoantigen evolution in cancer: immunoediting, immune escape, and future vaccine strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(6), 189741. https://doi.org/10.1016/j.bbcan.2026.189741
Vancouver
Martínez-Cortés F, Guzman Valle J, Maruri J, Martínez-Zarco BA, Domínguez-Romero AN, Gevorkian G, et al. Neoantigen evolution in cancer: immunoediting, immune escape, and future vaccine strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(6):189741. doi:10.1016/j.bbcan.2026.189741
BibTeX
@article{MartnezCorts2026,
author = {Martínez-Cortés, Fernando and Guzman Valle, Jesus and Maruri, Jorge and Martínez-Zarco, Braulio A and Domínguez-Romero, Allan Noé and Gevorkian, Goar and Manoutcharian, Karen},
title = {Neoantigen evolution in cancer: immunoediting, immune escape, and future vaccine strategies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {6},
pages = {189741},
doi = {10.1016/j.bbcan.2026.189741}
}
EUVIMED